Data gathered: December 21
AI Stock Analysis - Gilead Sciences (GILD)
Analysis generated September 16, 2024. Powered by Chat GPT.
Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops, manufactures, and commercializes innovative medicines. The company's primary areas of focus include antiviral therapeutics, particularly in the fields of HIV, hepatitis B and C, and influenza. Gilead has a rich portfolio of products and an active pipeline of investigational drugs, positioning itself as a key player in the biopharma industry.
Stock Alerts - Gilead Sciences (GILD)
 |
Gilead Sciences | December 18 Insider Alert: Dickinson Andrew D is continuing selling shares |
|
Gilead Sciences | December 4 Insider Alert: Dickinson Andrew D is selling shares |
|
Gilead Sciences | November 30 Insider Alert: Parsey Merdad is selling shares |
|
Gilead Sciences | November 28 Insider Alert: Bluestone Jeffrey is selling shares |
Alternative Data for Gilead Sciences
About Gilead Sciences
Gilead Sciences Inc is a biopharmaceutical company that discovers, develops and commercializes new medicines in areas of unmet medical need. Its products target a number of areas, such as HIV, liver diseases, cardiovascular and other diseases.
| Price | $92.57 |
| Target Price | Sign up |
| Volume | 19,690,000 |
| Market Cap | $114B |
| Year Range | $61.59 - $97.09 |
| Dividend Yield | 3.38% |
| PE Ratio | 1012.11 |
| Analyst Rating | 58% buy |
| Earnings Date | February 11 '25 |
| Industry | Biotechnology |
In the news
 |
Gilead Sciences to Present at Upcoming Investor ConferenceDecember 20 - Yahoo |
 |
Gilead Sciences (GILD) Gains As Market Dips: What You Should KnowDecember 19 - Yahoo |
Gilead Sciences : Submits New Drug Application to U.S. Food and Drug Administration for Twice-Yearly Lenacapavir for HIV PreventionDecember 19 - Finnhub |
|
 |
GILD's Trodelvy Gets Second Breakthrough Therapy Tag for Lung CancerDecember 17 - Yahoo |
 |
Analysts Set Gilead Sciences, Inc. (NASDAQ:GILD) PT at $96.43December 17 - ETF Daily News |
 |
Biotech Stock Roundup: Updates From GILD, REGN, GSK, ANAB Down on Study Data, EWTX GainsDecember 17 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 7.54B | 4.79B | 2.76B | 1.25B | -191M | 2.020 |
| Q2 '24 | 6.98B | 2.94B | 4.04B | 1.61B | 3.38B | 2.010 |
| Q1 '24 | 6.46B | 5.42B | 1.04B | -4.17B | 2.99B | -1.320 |
| Q4 '23 | 6.87B | 5.08B | 1.79B | 1.43B | 2.52B | 1.720 |
| Q3 '23 | 6.82B | 3.48B | 3.34B | 2.18B | 3.16B | 2.290 |
Insider Transactions View All
| Dickinson Andrew D filed to sell 132,373 shares at $92. December 17 '24 |
| Dickinson Andrew D filed to sell 266,849 shares at $92.8. December 3 '24 |
| Dickinson Andrew D filed to sell 138,919 shares at $92.8. December 3 '24 |
| Parsey Merdad filed to sell 91,200 shares at $91.8. November 29 '24 |
| Parsey Merdad filed to sell 94,399 shares at $91.8. November 29 '24 |
Similar companies
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Rohit Khanna Democrat |
Jun 5, 24 | Buy | $1K - $15K |
| Thomas Tuberville Republican |
May 15, 24 | Buy | $1K - $15K |
| Rohit Khanna Democrat |
May 6, 24 | Sell | $1K - $15K |
Read more about Gilead Sciences (GILD) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, lobbying cost, business outlook & linkedin employees.
What is the Market Cap of Gilead Sciences?
The Market Cap of Gilead Sciences is $114B.
What is Gilead Sciences' PE Ratio?
As of today, Gilead Sciences' PE (Price to Earnings) ratio is 1012.11.
When does Gilead Sciences report earnings?
Gilead Sciences will report its next earnings on February 11 '25.
What is the current stock price of Gilead Sciences?
Currently, the price of one share of Gilead Sciences stock is $92.57.
How can I analyze the GILD stock price chart for investment decisions?
The GILD stock price chart above provides a comprehensive visual representation of Gilead Sciences' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Gilead Sciences shares. Our platform offers an up-to-date GILD stock price chart, along with technical data analysis and alternative data insights.
Does GILD offer dividends to its shareholders?
Yes, Gilead Sciences (GILD) offers dividends to its shareholders, with a dividend yield of 3.38%. This dividend yield represents Gilead Sciences' commitment to providing value to its shareholders through both potential capital appreciation and steady income. Investors considering Gilead Sciences in their portfolio should factor in this dividend policy alongside the company's growth prospects and market position.
What are some of the similar stocks of Gilead Sciences?
Some of the similar stocks of Gilead Sciences are Amgen, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, Anavex Life Sciences, and BridgeBio Pharma.
.